Anbio Biotechnology
Every calculator, already run for NNNN
Open the full toolkit →You have the numbers on NNNN. Get the argument.
A written report on which of these readings actually decide the outcome for Anbio Biotechnology, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Ownership & short interest
Insider Trading Activity for NNNN
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Anbio Biotechnology
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in 2021 and is based in Frankfurt am Main, Germany.
NNNN — frequently asked
Is NNNN a buy right now?
Wall Street's consensus rating on Anbio Biotechnology is none. Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is NNNN overvalued?
NNNN trades at 53.6x trailing earnings. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
Compare Anbio Biotechnology against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Anbio Biotechnology
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full NNNN research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Anbio Biotechnology, in minutes. 3 free reports included with every account — no credit card required.